Antihistamines & Allergy Relief

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Fexofenadine Hydrochloride Tablets (120mg, 180mg) and Suspension (30mg/5ml) is a pure, non-sedating second-generation H1-receptor antagonist on the WHO Model List of Essential Medicines. It is the active carboxylic acid metabolite of terfenadine, but completely lacks terfenadine's cardiotoxicity (does NOT block cardiac HERG potassium channels or cause QT prolongation/Torsades de Pointes). Does not cross the blood-brain barrier. Indicated for relief of symptoms associated with seasonal allergic rhinitis (120 mg once daily) and chronic idiopathic urticaria (180 mg once daily).

Fexofenadine Hydrochloride Tablets (120mg, 180mg) and Suspension (30mg/5ml) is a pure, non-sedating second-generation H1-receptor antagonist on the WHO Model List of Essential Medicines. It is the active carboxylic acid metabolite of terfenadine, but completely lacks terfenadine's cardiotoxicity (does NOT block cardiac HERG potassium channels or cause QT prolongation/Torsades de Pointes). Does not cross the blood-brain barrier. Indicated for relief of symptoms associated with seasonal allergic rhinitis (120 mg once daily) and chronic idiopathic urticaria (180 mg once daily).

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.

Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Xylometazoline (0.1% w/v) and Oxymetazoline (0.5mg/ml) Nasal Drops / Spray is a topical sympathomimetic alpha-1 and alpha-2 adrenergic agonist nasal decongestant on the WHO Model List of Essential Medicines. It stimulates alpha-adrenergic receptors on post-capillary venules in the nasal mucosa, producing immediate vasoconstriction, shrinking engorged turbinates, reducing mucosal edema, and opening obstructed nasal airways within 2 to 5 minutes for up to 8 to 12 hours. Indicated for short-term relief of nasal congestion associated with common cold, sinusitis, allergic rhinitis, and otitis media.

Deflazacort Tablets (6mg) is an oral synthetic oxazoline derivative of prednisolone on the PMBI formulary. It exerts powerful anti-inflammatory and immunosuppressive actions with significantly lower bone mineral resorption, reduced osteoclastogenesis, and lower diabetogenic/weight gain liability compared to conventional prednisone or dexamethasone. Indicated for severe refractory bronchial asthma, allergic disorders, and Duchenne muscular dystrophy.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Saline Nasal Drops (Sodium Chloride 0.65% w/v isotonic/buffered solution) is a safe physiological nasal rinse on the WHO Model List framework. It moisturizes dry crusted nasal mucosa, thins tenacious mucus, flushes out airborne allergens, dust, and irritants, and restores natural mucociliary clearance without rebound congestion or systemic side effects. Indicated for nasal congestion, dry nasal passages, infant stuffy nose, sinusitis, and post-nasal surgery hygiene.

Fluticasone Propionate Respules (0.5mg per 2ml) is an inhaled corticosteroid nebulizer suspension on the WHO Model List framework. Delivers high topical anti-inflammatory potency to bronchial mucosal tissues. Indicated for maintenance management of severe persistent asthma and acute exacerbations in pediatric and adult patients unable to coordinate inhaler devices.

Montelukast Sodium (10mg) and Fexofenadine Hydrochloride (120mg Tablets, Suspension) is a non-sedating dual antiallergic combination. Fexofenadine is a pure second-generation H1-receptor antagonist that does not cross the blood-brain barrier (completely non-sedating), while montelukast blocks cysteinyl leukotriene CysLT1 receptors. Indicated for relief of symptoms associated with allergic rhinitis (sneezing, runny nose, itchy/watery eyes, nasal congestion) in patients needing daytime alertness.

Azelastine Hydrochloride (140mcg) and Fluticasone Propionate (50mcg) Nasal Spray is a fixed-dose second-generation H1-antihistamine and corticosteroid combination on the WHO Model List framework. Azelastine provides rapid-onset (within 15 minutes) blockade of histamine H1 receptors, relieving sneezing, nasal itching, and rhinorrhea. Fluticasone provides sustained 24-hour suppression of mucosal inflammation, relieving stubborn nasal congestion. Proven significantly superior to either monotherapy for Moderate-to-Severe Allergic Rhinitis and seasonal rhinoconjunctivitis.

Fluticasone Propionate / Fluticasone Furoate Nasal Spray (27.5mcg, 50mcg per spray) is a synthetic trifluorinated corticosteroid on the WHO Model List of Essential Medicines. It binds with exceptionally high affinity to glucocorticoid receptors in the nasal mucosa, inhibiting mediator release (histamine, leukotrienes, cytokines) with virtually negligible systemic oral bioavailability (<0.1%). Indicated for management of seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyposis.

Loratadine (10mg) and Desloratadine (5mg, 10mg) Tablets is a non-sedating second-generation tricyclic H1-antihistamine on the WHO Model List of Essential Medicines. Desloratadine is the active metabolite with >14-fold higher affinity for H1 receptors and an extended half-life of 27 hours. Indicated for symptomatic relief of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Xylometazoline (0.1% w/v) and Oxymetazoline (0.5mg/ml) Nasal Drops / Spray is a topical sympathomimetic alpha-1 and alpha-2 adrenergic agonist nasal decongestant on the WHO Model List of Essential Medicines. It stimulates alpha-adrenergic receptors on post-capillary venules in the nasal mucosa, producing immediate vasoconstriction, shrinking engorged turbinates, reducing mucosal edema, and opening obstructed nasal airways within 2 to 5 minutes for up to 8 to 12 hours. Indicated for short-term relief of nasal congestion associated with common cold, sinusitis, allergic rhinitis, and otitis media.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Ambroxol, Guaifenesin, and Bromhexine Expectorant Formulations (with Levosalbutamol or Terbutaline Syrup) is a comprehensive wet cough and mucociliary clearance formula on the PMBI formulary. Ambroxol stimulates pulmonary surfactant secretion by type II pneumocytes and depolymerizes mucopolysaccharides; bromhexine fragments mucin fibers; guaifenesin increases the volume and hydration of respiratory secretions, reducing mucus adhesiveness; and levosalbutamol/terbutaline relaxes bronchial smooth muscle. Indicated for productive wet cough associated with acute bronchitis, COPD, bronchiectasis, asthma, and tracheobronchitis.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Injection (22.75mg/ml) (Avil) is a parenteral first-generation alkylamine H1-antihistamine on the WHO Model List framework. It competitively blocks H1 receptors, rapidly relieving severe acute allergic reactions, angioedema, serum sickness, drug eruptions, and anaphylaxis (as adjunctive therapy following adrenaline).

Ebastine Tablets (10mg; alone or with Phenylephrine 10mg) is a long-acting, non-sedating second-generation H1-antihistamine. It is rapidly converted to active carebastine, providing durable 24-hour peripheral H1 blockade without anticholinergic or sedative impairment. Phenylephrine adds alpha-1 adrenergic nasal decongestion. Indicated for seasonal and perennial allergic rhinitis and chronic urticaria.

Formoterol Fumarate (6mcg) and Fluticasone Propionate (250mcg Inhaler / Powder for Inhalation) combines a rapid-onset, long-acting beta-2 agonist with a high-affinity synthetic fluorinated corticosteroid. Delivers fast bronchodilation within minutes along with comprehensive mucosal anti-inflammatory suppression. Indicated for regular maintenance treatment of persistent asthma in patients not adequately controlled on inhaled corticosteroids alone.

Hydroxyzine Hydrochloride Tablets (10mg, 25mg), Drops (6mg/ml), and Syrup (10mg/5ml) is a first-generation piperazine H1-antihistamine with potent central sedative, anxiolytic, and antipruritic properties on the WHO Model List of Essential Medicines. It blocks peripheral H1 receptors to suppress histamine-induced pruritus and urticaria, and suppresses subcortical CNS areas to alleviate acute anxiety. Indicated for symptomatic relief of severe pruritus associated with allergic conditions (chronic urticaria, atopic dermatitis, contact dermatitis), sedation prior to dental/surgical procedures, and management of generalized anxiety.

Diphenhydramine (13.5mg), Ammonium Chloride (135mg), Sodium Citrate (57mg), and Menthol Cough Syrup is a classic multi-action antitussive and expectorant syrup. Diphenhydramine provides central antitussive action and H1-antihistaminic relief; ammonium chloride is an irritant expectorant that liquefies bronchial secretions; sodium citrate acts as a mild systemic buffer; and menthol provides cooling soothing throat relief. Indicated for cough, cold, and throat irritation.

Acebrophylline Capsules / Tablets (100mg, 200mg Sustained Release; alone or with Montelukast 10mg or Acetylcysteine 600mg) is a fixed salt of ambroxol and theophylline-7-acetic acid on the PMBI formulary. It exerts a triple therapeutic action: potent bronchodilation via phosphodiesterase inhibition; mucoregulatory and surfactant-stimulating action via ambroxol (stimulating alveolar type II pneumocytes to produce pulmonary surfactant, reducing mucus viscosity and improving mucociliary clearance); and anti-inflammatory inhibition of phospholipase A2 and leukotriene C4. Indicated for bronchial asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic spastic bronchitis with thick viscid sputum.

Fluticasone Propionate / Fluticasone Furoate Nasal Spray (27.5mcg, 50mcg per spray) is a synthetic trifluorinated corticosteroid on the WHO Model List of Essential Medicines. It binds with exceptionally high affinity to glucocorticoid receptors in the nasal mucosa, inhibiting mediator release (histamine, leukotrienes, cytokines) with virtually negligible systemic oral bioavailability (<0.1%). Indicated for management of seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyposis.

Bepotastine Besilate (10mg) and Olopatadine (5mg) Tablets is an oral selective second-generation H1-receptor antagonist and mast cell stabilizer. It blocks peripheral H1 receptors and prevents mast cell degranulation, suppressing inflammatory cytokine (IL-5, leukotriene) release. Indicated for allergic rhinitis, pruritus, and chronic urticaria.

Bilastine Tablets (20mg) is a modern, highly selective second-generation H1-antihistamine on the PMBI formulary. It exhibits zero affinity for 30 other receptors (including muscarinic, adrenergic, serotonergic, and dopaminergic), does not cross the blood-brain barrier, does not undergo hepatic cytochrome P450 metabolism, and does not block cardiac potassium HERG channels. Indicated for symptomatic treatment of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria in adults and adolescents >=12 years.

Desloratadine (5mg) and Montelukast (10mg Tablets) combines the active descarboethoxyl metabolite of loratadine with a CysLT1 leukotriene antagonist. Indicated for allergic rhinitis and allergic asthma.

Fexofenadine Hydrochloride Tablets (120mg, 180mg) and Suspension (30mg/5ml) is a pure, non-sedating second-generation H1-receptor antagonist on the WHO Model List of Essential Medicines. It is the active carboxylic acid metabolite of terfenadine, but completely lacks terfenadine's cardiotoxicity (does NOT block cardiac HERG potassium channels or cause QT prolongation/Torsades de Pointes). Does not cross the blood-brain barrier. Indicated for relief of symptoms associated with seasonal allergic rhinitis (120 mg once daily) and chronic idiopathic urticaria (180 mg once daily).

Formoterol Fumarate (6mcg) and Fluticasone Propionate (250mcg Inhaler / Powder for Inhalation) combines a rapid-onset, long-acting beta-2 agonist with a high-affinity synthetic fluorinated corticosteroid. Delivers fast bronchodilation within minutes along with comprehensive mucosal anti-inflammatory suppression. Indicated for regular maintenance treatment of persistent asthma in patients not adequately controlled on inhaled corticosteroids alone.

Hydroxyzine Hydrochloride Tablets (10mg, 25mg), Drops (6mg/ml), and Syrup (10mg/5ml) is a first-generation piperazine H1-antihistamine with potent central sedative, anxiolytic, and antipruritic properties on the WHO Model List of Essential Medicines. It blocks peripheral H1 receptors to suppress histamine-induced pruritus and urticaria, and suppresses subcortical CNS areas to alleviate acute anxiety. Indicated for symptomatic relief of severe pruritus associated with allergic conditions (chronic urticaria, atopic dermatitis, contact dermatitis), sedation prior to dental/surgical procedures, and management of generalized anxiety.

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Loratadine (10mg) and Desloratadine (5mg, 10mg) Tablets is a non-sedating second-generation tricyclic H1-antihistamine on the WHO Model List of Essential Medicines. Desloratadine is the active metabolite with >14-fold higher affinity for H1 receptors and an extended half-life of 27 hours. Indicated for symptomatic relief of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Doxofylline Tablets (400mg; alone or with Montelukast 10mg) is a novel xanthine derivative bronchodilator on the PMBI formulary. Unlike theophylline, it contains a dioxolane group at position 7 that specifically inhibits phosphodiesterase without binding to adenosine receptors or interfering with calcium influx. This confers potent bronchodilatory and anti-inflammatory activity with dramatically fewer cardiac, gastric, and CNS side effects (negligible tachycardia, insomnia, or gastric hypersecretion) and a 10-fold wider therapeutic window. Indicated for maintenance treatment of bronchial asthma, COPD, and spastic bronchitis.

Mometasone Furoate Aqueous Nasal Spray (0.05% w/v / 50mcg per actuation) is a topically active synthetic glucocorticoid on the WHO Model List of Essential Medicines. It exhibits high topical anti-inflammatory potency on nasal mucosa with undetectable systemic bioavailability (<0.1%), downregulating pro-inflammatory cytokines and allergic cellular infiltration. Indicated for treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children >=2 years, and treatment of nasal polyps in adults >=18 years.

Bilastine (10mg/20mg) and Montelukast (4mg/10mg Tablets, Orodispersible Tablets) is a modern, non-sedating antiallergic combination. Bilastine is a highly selective second-generation H1-antihistamine with zero anticholinergic activity and no blood-brain barrier penetration; montelukast blocks cysteinyl leukotrienes. Indicated for allergic rhinitis and chronic urticaria.

Dihydralazine Hydrochloride Tablets (25mg) is an oral direct-acting peripheral arteriolar vasodilator on the WHO Model List framework. It relaxes arteriolar smooth muscle to reduce systemic vascular resistance and blood pressure. Indicated for moderate-to-severe hypertension and pulmonary arterial hypertension.

Caffeine (30mg) + Diphenhydramine (25mg) + Paracetamol (500mg) + Phenylephrine (5mg) Tablets is an established pharmaceutical agent in the Respiratory & Allergy category on the PMBI National Formulary. Formulated to treat obstructive airway disease, cough, or allergic disorders according to verified pharmacopoeial standards.

Salmeterol Xinafoate (25mcg/50mcg) and Fluticasone Propionate (100mcg/250mcg/500mcg Inhaler, Rotacaps) is a benchmark inhaled corticosteroid and long-acting beta-2 agonist combination on the WHO Model List of Essential Medicines. Fluticasone exerts profound local anti-inflammatory, immunosuppressive, and anti-edematous effects in bronchial mucosa with low systemic bioavailability due to extensive first-pass metabolism. Salmeterol provides long-acting bronchodilation lasting over 12 hours via persistent beta-2 receptor activation. Indicated for maintenance therapy of persistent bronchial asthma and maintenance treatment of airflow obstruction in patients with severe COPD and recurrent exacerbations.

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Bilastine (10mg/20mg) and Montelukast (4mg/10mg Tablets, Orodispersible Tablets) is a modern, non-sedating antiallergic combination. Bilastine is a highly selective second-generation H1-antihistamine with zero anticholinergic activity and no blood-brain barrier penetration; montelukast blocks cysteinyl leukotrienes. Indicated for allergic rhinitis and chronic urticaria.

Ebastine Tablets (10mg; alone or with Phenylephrine 10mg) is a long-acting, non-sedating second-generation H1-antihistamine. It is rapidly converted to active carebastine, providing durable 24-hour peripheral H1 blockade without anticholinergic or sedative impairment. Phenylephrine adds alpha-1 adrenergic nasal decongestion. Indicated for seasonal and perennial allergic rhinitis and chronic urticaria.

Hydroxyzine Hydrochloride Tablets (10mg, 25mg), Drops (6mg/ml), and Syrup (10mg/5ml) is a first-generation piperazine H1-antihistamine with potent central sedative, anxiolytic, and antipruritic properties on the WHO Model List of Essential Medicines. It blocks peripheral H1 receptors to suppress histamine-induced pruritus and urticaria, and suppresses subcortical CNS areas to alleviate acute anxiety. Indicated for symptomatic relief of severe pruritus associated with allergic conditions (chronic urticaria, atopic dermatitis, contact dermatitis), sedation prior to dental/surgical procedures, and management of generalized anxiety.

Hydroxyzine Hydrochloride Tablets (10mg, 25mg), Drops (6mg/ml), and Syrup (10mg/5ml) is a first-generation piperazine H1-antihistamine with potent central sedative, anxiolytic, and antipruritic properties on the WHO Model List of Essential Medicines. It blocks peripheral H1 receptors to suppress histamine-induced pruritus and urticaria, and suppresses subcortical CNS areas to alleviate acute anxiety. Indicated for symptomatic relief of severe pruritus associated with allergic conditions (chronic urticaria, atopic dermatitis, contact dermatitis), sedation prior to dental/surgical procedures, and management of generalized anxiety.

Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.

Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.

Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Montelukast (10mg) and Ebastine (10mg Tablets) combines a long-acting second-generation H1-blocker (prodrug of carebastine) with a CysLT1 leukotriene receptor antagonist. Provides sustained 24-hour symptom relief in allergic rhinitis and chronic idiopathic urticaria.

Loratadine (10mg) and Desloratadine (5mg, 10mg) Tablets is a non-sedating second-generation tricyclic H1-antihistamine on the WHO Model List of Essential Medicines. Desloratadine is the active metabolite with >14-fold higher affinity for H1 receptors and an extended half-life of 27 hours. Indicated for symptomatic relief of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Pheniramine Maleate Tablets (25mg) and Dexchlorpheniramine Tablets (2mg, 6mg Sustained Release) is an oral first-generation H1-antihistamine with anticholinergic and moderate sedative properties. Indicated for allergic rhinitis, urticaria, acute allergic skin eruptions, and drug rashes.

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Cetirizine Hydrochloride Tablets (5mg, 10mg) and Syrup (5mg/5ml) is a second-generation piperazine H1-antihistamine and active carboxylated metabolite of hydroxyzine on the WHO Model List of Essential Medicines. It selectively antagonizes peripheral H1 receptors, blocking histamine-induced wheal, flare, capillary permeability, and sensory nerve activation, while also inhibiting late-phase cutaneous and bronchial eosinophil recruitment. Indicated for relief of symptoms associated with seasonal and perennial allergic rhinitis, allergic conjunctivitis, and chronic idiopathic urticaria.

Montelukast Sodium (10mg) and Fexofenadine Hydrochloride (120mg Tablets, Suspension) is a non-sedating dual antiallergic combination. Fexofenadine is a pure second-generation H1-receptor antagonist that does not cross the blood-brain barrier (completely non-sedating), while montelukast blocks cysteinyl leukotriene CysLT1 receptors. Indicated for relief of symptoms associated with allergic rhinitis (sneezing, runny nose, itchy/watery eyes, nasal congestion) in patients needing daytime alertness.

Bepotastine Besilate (10mg) and Olopatadine (5mg) Tablets is an oral selective second-generation H1-receptor antagonist and mast cell stabilizer. It blocks peripheral H1 receptors and prevents mast cell degranulation, suppressing inflammatory cytokine (IL-5, leukotriene) release. Indicated for allergic rhinitis, pruritus, and chronic urticaria.

Rupatadine (10mg) and Montelukast (10mg Tablets) is a dual H1-receptor and Platelet-Activating Factor (PAF) antagonist combined with a leukotriene antagonist. Simultaneously blocks three distinct allergic mediators (histamine, PAF, and LTD4), delivering powerful relief in severe allergic rhinitis and urticaria.

Rupatadine Tablets (10mg) is a modern second-generation antihistamine with dual H1-receptor and Platelet-Activating Factor (PAF) antagonist properties. By blocking both histamine and PAF receptors, it provides comprehensive suppression of allergic vascular leakage, platelet aggregation, and mucosal inflammation. Indicated for allergic rhinitis and chronic urticaria.